1476028-21-3

Basic information

• Product Name: (S)-4-Boc-3-carbaMoylMorpholine
• Synonyms: (S)-4-Boc-3-carbaMoylMorpholine
• CAS NO: 1476028-21-3
• Molecular Formula: C10H18N2O4
• Molecular Weight: 230.26
• Mol File: 1476028-21-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-4-Boc-3-carbaMoylMorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-Boc-3-carbaMoylMorpholine(1476028-21-3)
• EPA Substance Registry System: (S)-4-Boc-3-carbaMoylMorpholine(1476028-21-3)

Safety Data

• Hazardous Substances Data: 1476028-21-3(Hazardous Substances Data)

Usage

General Description

(S)-4-Boc-3-carbaMoylMorpholine is a chemical compound with the molecular formula C10H19NO4. It is a derivative of morpholine and is commonly used as a building block in organic synthesis. The compound is a white to off-white solid that is soluble in organic solvents such as methanol and dichloromethane. It is commonly used as a reagent in the synthesis of pharmaceuticals and other organic compounds. The Boc (tert-butoxycarbonyl) protecting group gives the compound stability, allowing for selective deprotection during chemical reactions. (S)-4-Boc-3-carbaMoylMorpholine is a versatile compound with applications in the pharmaceutical and chemical industries.

Upstream product

• 783350-37-8 (S)-4-[(tert-butoxy)carbonyl]morpholine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 106825-79-0 (S)-morpholine-3-carboxylic acid 
• 77873-76-8 morpholine-3-carboxylic acid 
• 212650-43-6 4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid 

Downstream Products

• 518047-40-0 tert-butyl 3-cyanomorpholine-4-carboxylate 
• 518058-62-3 tert-butyl 3-[amino(hydroxyimino)methyl]morpholine-4-carboxylate 
• 848488-74-4 morpholine-3-carboxamide 

Relevant articles and documents

Dihydropyrimidine compounds and their use in medicine (by machine translation)

The invention relates to a dihydropyrimidine compounds and their use as medicaments, in particular for the treatment and prevention of hepatitis b use of the medicament. In particular, the invention relates to the general formula (I) or (Ia) compound of formula or its enantiomer, non-enantiomeric isomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt, wherein the variables are defined in the specification. The invention also relates to the general formula (I) or (Ia) compound of formula or its enantiomer, non-enantiomeric isomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt as the pharmaceutical use, especially for the treatment and prevention of hepatitis b use of the medicament. (by machine translation)

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

BETA CARBOLINES AND USES THEREOF

This invention provides beta-carboline compounds of formula I: wherein R1, R2, R3, R4, R5, G, and x are as described in the specification. The compounds are useful for treating cancer and inflammatory disorders.